Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.62 |
| ▸ | MMEL1 | Q495T6 | 7/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875545 | 1.00 | MME (0.62) | MMEMMEL1ATM | |
| SCHEMBL2878307 | 0.91 | MMEL1 (0.67) | MMEMMEL1ATM | |
| SCHEMBL8552371 | 0.88 | MME (0.50) | MMEMMEL1 | |
| SCHEMBL19190257 | 0.88 | MME (0.53) | MME | |
| SCHEMBL17011376 | 0.88 | MME (0.53) | MME | |
| SCHEMBL2875424 | 0.88 | MMEL1 (0.72) | MMEMMEL1ATM | |
| SCHEMBL16942452 | 0.88 | MME (0.48) | MMEMMEL1 | |
| SCHEMBL15474326 | 0.86 | MME (0.60) | MMEMMEL1 | |
| SCHEMBL19696010 | 0.86 | MME (0.60) | MMEMMEL1 | |
| SCHEMBL19086104 | 0.86 | MME (0.60) | MMEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| EP-2956464-B1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| EP-2956464-B1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170015688-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015688-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015688-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9480693-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2016-11-01 | — | — | US | disclosed |
| US-9480693-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2016-11-01 | — | — | US | disclosed |
| US-9480693-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2016-11-01 | — | — | US | disclosed |
| US-20150374726-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2015-12-31 | — | — | US | disclosed |
| US-20150374726-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2015-12-31 | — | — | US | disclosed |
| EP-2956464-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | Novartis AG (CH) | 2015-12-23 | — | — | EP | disclosed |
| US-9163040-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-9163040-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-9163040-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| WO-2014126979-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014126979-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228323-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228323-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228323-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885ATM 4819/4885 |
| US-20150374726-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885ATM 4819/4885 |
| US-20170015688-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885ATM 4819/4885 |
| US-20140228323-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885ATM 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.